ERBB2 and metastatic neoplasm: DESTINY-Breast-06 is a phase III trial involving ER+/HER2 low or ultralow (IHC 0 with membrane staining) metastatic breast cancer patients progressing after one or more lines of ET with no previous chemotherapy for metastatic disease.